What was known before {#section21-2054358119875462}
=====================

Short-term graft and patient-survival rates have improved since the introduction of newer immunosuppressive therapies. Center variation in kidney transplantation outcomes has been described; however, potential contributing center factors have not been studied well.

What this adds {#section22-2054358119875462}
==============

This is the first Canadian study to examine center variation after kidney transplantation in a cohort of patients who were transplanted exclusively beyond the year 2000 who had up to 10 years of follow-up.

Introduction {#section23-2054358119875462}
============

Between-center variation in graft and patient-survival rates have been observed in studies from the United States,^[@bibr1-2054358119875462][@bibr2-2054358119875462]-[@bibr3-2054358119875462]^ Canada,^[@bibr4-2054358119875462]^ and Europe.^[@bibr5-2054358119875462][@bibr6-2054358119875462]-[@bibr7-2054358119875462]^ Specific methods that have been applied to measure and compare center outcomes in kidney transplantation include descriptive analyses such as Kaplan-Meier survival curves or cumulative incidence as well as comparative analyses including standardization and regression modeling.^[@bibr8-2054358119875462],[@bibr9-2054358119875462]^ In the United States, program-specific report cards for each transplantation center are published every 6 months by the Scientific Registry of Transplant recipients.^[@bibr10-2054358119875462]^ This report card includes both unadjusted survival rates as well as an adjusted standardized ratio of the observed to expected events (graft losses and deaths) for each center compared with the national average.^[@bibr11-2054358119875462][@bibr12-2054358119875462][@bibr13-2054358119875462]-[@bibr14-2054358119875462]^ The standardized ratios use Cox regression modeling to incorporate the effect of different important patient covariates on the outcome as well as to calculate the expected number of events.^[@bibr15-2054358119875462],[@bibr16-2054358119875462]^ This method ensures that a transplant center is not unnecessarily penalized due to the type of patient population it serves.

While the role of patient characteristics (both recipient and donor) at the time of transplant have been well examined,^[@bibr1-2054358119875462],[@bibr2-2054358119875462],[@bibr4-2054358119875462],[@bibr5-2054358119875462],[@bibr7-2054358119875462],[@bibr17-2054358119875462]^ center-level factors which may contribute to variation have not been extensively examined. To date, studies examining center-level factors, including center volume^[@bibr3-2054358119875462],[@bibr4-2054358119875462],[@bibr17-2054358119875462][@bibr18-2054358119875462][@bibr19-2054358119875462][@bibr20-2054358119875462]-[@bibr21-2054358119875462]^ and center type^[@bibr22-2054358119875462],[@bibr23-2054358119875462]^ (eg, for profit or teaching hospital), have found conflicting results. Many of the studies that assessed the center volume--outcome relationship included patients transplanted before 2001,^[@bibr1-2054358119875462],[@bibr3-2054358119875462],[@bibr4-2054358119875462],[@bibr17-2054358119875462],[@bibr19-2054358119875462][@bibr20-2054358119875462]-[@bibr21-2054358119875462]^ which may be less relevant, given changes in practice over time.

The objectives of this study are to compare the graft and patient survival rates across 5 transplant centers in Ontario, Canada, to determine if center volume is associated with transplant outcomes and to determine whether center volume explained center variation after accounting for case mix. An additional objective was to determine whether the provider characteristics such as type of provider and provider experience are associated with graft and patient outcomes and contribute to center variation. We hypothesized that higher center volume would be associated with improved graft and patient survival.

Methods {#section24-2054358119875462}
=======

Study Design and Setting {#section25-2054358119875462}
------------------------

We conducted a population-based retrospective observational cohort study using health care databases at the Institute for Clinical Evaluative Sciences (ICES) in Ontario, Canada. Ontario has a population of approximately 13.6 million residents who have universal access to health care services. There are currently 6 kidney transplant centers in Ontario, Canada. The use of data in this project was authorized under section 45 of Ontario's Personal Health Information Protection Act, which does not require a review by a research ethics board. The reporting of this study followed the Strengthening the Reporting of Observational Studies in Epidemiology and Reporting of Studies Conducted using Observational Routinely-Collected Health Data reporting guidelines.^[@bibr24-2054358119875462],[@bibr25-2054358119875462]^ The full data set creation plan and underlying analytic code are available from the authors upon request, understanding that the programs may rely on coding templates or macros that are unique to ICES.

Data Sources {#section26-2054358119875462}
------------

We used 4 linked data sets to create the cohort and to obtain patient, center, provider, and outcome data as previously described.^[@bibr26-2054358119875462]^ These data sets were linked using unique encoded identifiers and were analyzed at the ICES. We used the Canadian Organ Replacement Register (CORR) to identify kidney transplant recipients as well as determine certain patient-level characteristics. The CORR's sensitivity to correctly identify kidney transplant recipients is 96% and positive predictive value is 98%.^[@bibr27-2054358119875462]^ Demographic and vital status of kidney transplant recipients were obtained using the Ontario Registered Persons Database. The Canadian Institute for Health Information Discharge Abstract Database and the Ontario Health Insurance Plan (OHIP) were used to obtain information on recipient comorbidities and outcomes. These were determined using codes that were similar to those used in previous kidney transplant studies ([Supplemental Table S1](https://journals.sagepub.com/doi/suppl/10.1177/2054358119875462)).^[@bibr27-2054358119875462][@bibr28-2054358119875462]-[@bibr29-2054358119875462]^

Study Cohort {#section27-2054358119875462}
------------

The creation of this study cohort has been previously described.^[@bibr26-2054358119875462]^ In brief, we included all adults (≥18 years) who received a first-time solitary kidney transplant in Ontario, Canada, between January 1, 2000 and December 31, 2013. We excluded those with an invalid ICES key number (IKN; a confidential ICES patient number), or who were not from Ontario, died before transplant date, had unknown age or sex, and whose OHIP transplant billing or hospitalization dates did not align with transplant date ([Supplemental Figure S1](https://journals.sagepub.com/doi/suppl/10.1177/2054358119875462)). For this study, we excluded a center due to the small volume of transplants performed over the study period (n = 55).

Definition of Patient, Center, and Provider Characteristics {#section28-2054358119875462}
-----------------------------------------------------------

Transplant recipients were classified by the center at which their transplant occurred using the CORR facility code number. Information on the transplant center was obtained using CORR and OHIP. The surgical transplant fee code has been validated for identifying kidney transplant recipients.^[@bibr23-2054358119875462]^

Outcomes {#section29-2054358119875462}
--------

Patients were followed from the date of transplant until March 31, 2015. The co-primary outcomes were death-censored graft loss and total mortality. Total mortality included any death that occurred during follow-up, even if after the allograft had failed.

Statistical Analysis {#section30-2054358119875462}
--------------------

We used descriptive statistics to summarize characteristics of patients at the time of transplant by center and by the entire cohort. Continuous variables were described using mean and standard deviation (SD) when the data followed a normal distribution or median and interquartile range if skewed. Frequencies and percentages were used for categorical data.

To describe the distribution of center volume over time, we categorized the study period into 3 eras: the first time period was from January 1, 2000 to December 31, 2004; the second was from January 1, 2005 to June 30, 2009; and the third was July 1, 2009 to December 30, 2013. Distribution of center volume within each time era was compared across centers using the chi-squared test. The 1-, 5-, and 10-year survival distributions were described per center using the Kaplan-Meier method, and statistical significance of differences across centers was assessed using the log-rank test.

To statistically examine variation in outcomes across transplant centers, while accounting for differences in patient case mix, we used the fixed-effects multivariable Cox proportional hazards regression. Fixed-effects modeling was used because of the limited number of centers available for analysis (ie, 5). We first calculated unadjusted center hazard ratios (HRs) for both co-primary outcomes (death-censored graft loss and total mortality). To account for differences in patient case mix, we obtained adjusted HR with 95% confidence intervals (CIs) for each transplant center, using effects coding to express differences relative to the average across all centers. The statistical significance of differences across centers was examined using Wald tests. We adjusted for the following patient case mix factors: recipient age, sex, race (categorized Caucasian, African, Asian compared to other) cause of end-stage renal disease (ESRD), body mass index (BMI), Charlson Comorbidity Index, pretransplant dialysis modality (none vs hemodialysis or peritoneal dialysis), years on dialysis before transplantation, era of transplant (as defined previously), donor source (living vs deceased), and donor age. Centers having HRs with both upper and lower confidence limits less than 1 imply that the center has a survival rate significantly better than the average after accounting for patient case mix, while HRs for centers with both limits greater than 1 imply that the center is performing significantly worse than the average. On the contrary, centers with CIs including 1 have a survival rate that is not significantly different than the average after accounting for patient case mix.

To statistically examine whether center volume explained any additional variation in outcomes across transplant centers, after accounting for differences in patient case mix, we then added center volume to the Cox regression models. We examined the statistical significance of center volume as an independent predictor of outcomes in these models, as well as the extent to which the differences in center-specific HRs are attenuated through the addition of center volume. In these models, center volume was defined as the total number of transplants performed at a given center in the calendar year *prior* to a patient's transplant. Center volume was specified as continuous variables to avoid losing meaningful information and power through categorization.^[@bibr30-2054358119875462]^ To interpret the resulting HRs in a clinically relevant manner, HRs for volume were expressed in units of 25 transplants performed. While we wanted to examine the association between provider characteristics and transplant outcomes, this was not possible because there was not one specific provider who was most responsible for the patient's care.

Data were missing for the following variables: recipient race (10.0%), cause of ESRD (7.9%), Charlson Comorbidity Index (5.5%), BMI (16.9%), donor type (0.75%), and donor age (0.75%). Before analysis, we performed a multiple imputation using the fully conditional specification method which does not assume a joint distribution for all variables in the imputation model but instead applies a separate conditional distribution for each of the variables to be imputed.^[@bibr31-2054358119875462]^ For categorical variables, we used the discriminant method and for continuous variables, linear regression. We conducted 10 imputations using 100 burn-in iterations. Multivariable analyses were conducted for each imputation data set and combined across data sets using Rubin's rules.^[@bibr32-2054358119875462]^ All statistical analyses were performed using SAS (Statistical Analysis Software) version 9.4 (SAS Institute, Cary, NC). A 2-sided *P* value \< .05 was considered statistically significant.

Results {#section31-2054358119875462}
=======

Patient, Center, and Provider Characteristics at the Time of Transplant {#section32-2054358119875462}
-----------------------------------------------------------------------

The study included 5037 primary kidney transplant recipients from 5 transplant centers in Ontario. The mean (SD) age of the overall cohort was 50.9 (13.5) years, 63.1% were male and 63.4% were Caucasian ([Table 1](#table1-2054358119875462){ref-type="table"}). The characteristics of the transplant population across centers have previously been reported.^[@bibr26-2054358119875462]^ The percentage of different ethnic groups did vary significantly by center. For example, the total percentage of Caucasians transplanted at a given center ranged between 47.8% and 79.4%, whereas total percentage of Asians ranged between 2.5% and 13.1%. The annual transplant volume varied by transplant center and time era of transplant ([Table 1](#table1-2054358119875462){ref-type="table"}).

###### 

Participant Characteristics at the Time of Kidney Transplant (n = 5037).

![](10.1177_2054358119875462-table1)

  Characteristic                                                                           Overall cohort     Range across centers
  ---------------------------------------------------------------------------------------- ------------------ -----------------------------------
  Age, mean (SD)                                                                           50.9 (13.5)        50.5 (13.6)-51.5 (13.1)
  Sex, male, No. (%)                                                                       3177 (63.1)        60.1%-65.4%
  Race, No. (%)                                                                                               
   Caucasian                                                                               3194 (63.4)        47.8%-79.4%
   African                                                                                 361 (7.2)          1.3%-11.1%
   Asian                                                                                   345 (6.8)          2.5%-13.1%
   Other^[@bibr1-2054358119875462]^                                                        634 (12.6)         5.5%-18.9%
  Cause of ESRD, No. (%)                                                                                      
   Glomerulonephritis                                                                      1684 (33.4)        30.8%-36.1%
   Diabetes                                                                                990 (19.7)         15.8%-25.0%
   Cystic kidney                                                                           680 (13.5)         11.2%-15.1%
   Renal vascular                                                                          553 (11.0)         7.2%-14.0%
  BMI, mean (SD)                                                                           26.6 (5.7)         25.5 (5.3)-27.6 (6.1)
  Charlson Index, mean (SD)                                                                2.7 (1.3)          2.6 (1.3)-2.8 (1.3)
  Pretransplant dialysis modality,^[@bibr2-2054358119875462]^ No. (%)                                         
   Preemptive                                                                              515 (10.2)         3.6%-13.2%
   Dialysis pretransplant                                                                  4522 (89.8)        86.8%-96.4%
  Years on dialysis, median \[IQR\]                                                        2.7 \[1.1, 5.1\]   1.8 \[1.1, 3.0\]-4.2 \[1.3, 6.6\]
  Donor type, No. (%)                                                                                         
   Living                                                                                  2115 (42.0)        22.7%-50.3%
   Deceased^[a](#table-fn2-2054358119875462){ref-type="table-fn"}^                         2922 (58.0)        49.7%-77.3%
  Donor age, mean (SD)                                                                                        
   Living                                                                                  44.5 (13.3)        42.8 (12.2)-46.9 (15.3)
   Deceased                                                                                45.5 (15.9)        43.4 (15.9)-48.8 (16.2)
  Time era of transplant,^[b](#table-fn3-2054358119875462){ref-type="table-fn"}^ No. (%)                      
   2000-2004                                                                               1404 (27.9)        26.0%-33.8%
   2005-2009                                                                               1659 (32.9)        31.5%-34.7%
   2009-2013                                                                               1974 (39.2)        34.7%-42.2%
  Annual mean (SD) volume over the study period                                            77.6 (27.0)        51.5 (9.3)-101.7 (23.9)

*Note.* ESRD = end-stage renal disease; BMI = body mass index; IQR = interquartile range.

Total number for deceased also includes those with missing donor type.

The first time period is 5 years, and the second two are 4½ years.

Other^[@bibr1-2054358119875462]^ includes Aboriginal, Indian subcontinent, Pacific Islander, Other/Multiracial. Pretransplant dialysis^[@bibr2-2054358119875462]^ includes both peritoneal dialysis and hemodialysis.

Observed Survival Rates {#section33-2054358119875462}
-----------------------

### Outcomes---Death-censored graft loss and total mortality {#section34-2054358119875462}

Over the study period, 807 (16.0%) patients experienced graft loss, and there were 921 (18.3%) deaths. The overall observed death-censored graft-survival rates ranged between 75.8% and 85.8% at 10 years after transplantation and differed significantly across centers (log-rank *P* = .001; [Table 2](#table2-2054358119875462){ref-type="table"}). The overall observed patient survival rates ranged between 67.5% and 76.7% at 10 years after transplantation and varied significantly across centers (log-rank *P* \< .0001; [Table 2](#table2-2054358119875462){ref-type="table"}; [Figures 1](#fig1-2054358119875462){ref-type="fig"} and [2](#fig2-2054358119875462){ref-type="fig"}).

###### 

Death-Censored Graft Loss and Patient-Survival Rates Across Centers at 1, 5, and 10 Years After Transplantation.

![](10.1177_2054358119875462-table2)

  By center number                                                                                                              1              2              3              4              5
  ----------------------------------------------------------------------------------------------------------------------------- -------------- -------------- -------------- -------------- --------------
  Death-censored graft loss---Observed survival rates ± standard error^[a](#table-fn5-2054358119875462){ref-type="table-fn"}^                                                               
   1 year                                                                                                                       92.9 ± 0.007   95.5 ± 0.008   92.6 ± 0.009   94.9 ± 0.007   92.1 ± 0.008
   5 year                                                                                                                       86.3 ± 0.01    90.4 ± 0.01    83.3 ± 0.01    88.6 ± 0.01    86.9 ± 0.01
   10 year                                                                                                                      78.2 ± 0.02    83.9 ± 0.02    75.8 ± 0.02    79.6 ± 0.02    76.3 ± 0.02
  Total Mortality---Observed survival rates ± standard error^[b](#table-fn6-2054358119875462){ref-type="table-fn"}^                                                                         
   1 year                                                                                                                       98.1 ± 0.004   97.2 ± 0.006   96.6 ± 0.007   97.3 ± 0.005   97.4 ± 0.005
   5 year                                                                                                                       90.6 ± 0.009   86.4 ± 0.02    87.7 ± 0.01    86.8 ± 0.01    90.3 ± 0.008
   10 year                                                                                                                      76.7 ± 0.02    69.5 ± 0.02    67.5 ± 0.02    67.7 ± 0.02    75.8 ± 0.02

Overall *P* = .001.

Overall *P* \< .0001.

![Death-censored graft-survival curves by center.](10.1177_2054358119875462-fig1){#fig1-2054358119875462}

![Patient-survival curves by center.](10.1177_2054358119875462-fig2){#fig2-2054358119875462}

Unadjusted and Adjusted Hazard Ratios {#section35-2054358119875462}
-------------------------------------

### Outcomes---Death-censored graft loss and total mortality {#section36-2054358119875462}

Results from the multivariable Cox proportional hazards regression analyses for death-censored graft loss are presented in [Table 3](#table3-2054358119875462){ref-type="table"}. Center-specific HRs and 95% CIs obtained from these analyses are displayed graphically in [Figure 3](#fig3-2054358119875462){ref-type="fig"}, showing variation across centers before adjusting for patient case mix, and then after adjusting for patient case mix alone, and patient case mix plus center volume. The results showed that raw center-specific HRs for death-censored graft loss varied significantly across centers (*P* = .001), from a minimum of 0.76 to a maximum of 1.24 ([Figure 3A](#fig3-2054358119875462){ref-type="fig"}). Patient case mix factors found to be significantly associated with death-censored graft survival in multivariable models were recipient age, BMI, Charlson Index, pretransplant time on dialysis, donor type, and donor age. While in univariate (unadjusted models) for the outcome death-censored graft loss being of African ethnicity had worse graft survival, HR 1.37 (1.01-1.84), compared to the reference group, in the multivariable models, this finding was no longer significant. After accounting for patient case mix, differences across centers still ranged substantially from 0.78 to 1.18. Center volume was not statistically significantly associated with graft loss (HR = 0.90; 95% CI, 0.78-1.04).

###### 

Center-Specific Patient Hazard Ratios From Multivariable Cox Proportional Hazards Regression Analysis for Graft Loss Censoring at Time of Death Over Full Follow-Up (Total Number of Events = 807).

![](10.1177_2054358119875462-table3)

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Covariate                                                                       Unadjusted\        Adjusting for patient case mix only (n = 5037)   Adjusting for patient case mix and center volume (n = 5037)
                                                                                  (n = 5037)                                                          
  ------------------------------------------------------------------------------- ------------------ ------------------------------------------------ -------------------------------------------------------------
  Age, (per 5-year increase)                                                      0.96 (0.94-0.99)   0.92 (0.89-0.95)                                 0.92 (0.89-0.95)

  Sex                                                                                                                                                 

   Female                                                                         1.03 (0.89-1.18)   1.08 (0.93-1.24)                                 1.07 (0.93-1.24)

   Male                                                                           Reference          Reference                                        Reference

  Race                                                                                                                                                

   Caucasian                                                                      0.97 (0.78-1.20)   1.13 (0.90-1.44)                                 1.13 (0.89-1.43)

   African                                                                        1.37 (1.01-1.84)   1.31 (0.96-1.77)                                 1.30 (0.96-1.77)

   Asian                                                                          1.15 (0.84-1.56)   1.19 (0.86-1.65)                                 1.19 (0.86-1.65)

   Other^[a](#table-fn8-2054358119875462){ref-type="table-fn"}^                   Reference          Reference                                        Reference

  Cause of ESRD                                                                                                                                       

   GN                                                                             1.00 (0.82-1.22)   0.93 (0.75-1.16)                                 0.93 (0.75-1.16)

   Diabetes                                                                       1.02 (0.82-1.28)   0.86 (0.66-1.13)                                 0.86 (0.66-1.13)

   Cystic                                                                         0.63 (0.48-0.82)   0.69 (0.52-0.91)                                 0.69 (0.52-0.91)

   RVD                                                                            1.01 (0.78-1.30)   0.96 (0.72-1.27)                                 0.96 (0.72-1.27)

   Other                                                                          Reference          Reference                                        Reference

  BMI                                                                             1.01 (0.99-1.02)   1.02 (1.00-1.03)                                 1.02 (1.00-1.03)

  Charlson Index                                                                  1.13 (1.07-1.19)   1.13 (1.06-1.21)                                 1.13 (1.06-1.21)

  Preemptive transplant                                                           0.52 (0.39-0.68)   0.77 (0.56-1.05)                                 0.77 (0.56-1.05)

  Pretransplant dialysis^[b](#table-fn9-2054358119875462){ref-type="table-fn"}^   Reference          Reference                                        Reference

  Time on dialysis pretransplant (per 1-year increase)                            1.00 (1.00-1.00)   1.03 (1.00-1.06)                                 1.03 (1.00-1.06)

  Donor type                                                                                                                                          

   Living                                                                         0.68 (0.59-0.78)   0.73 (0.61-0.87)                                 0.73 (0.61-0.87)

   Deceased                                                                       Reference          Reference                                        Reference

  Donor age (per 5-year increase)                                                 1.05 (1.03-1.07)   1.06 (1.04-1.09)                                 1.06 (1.04-1.09)

  Time era of transplant                                                                                                                              

   2000-2004                                                                      Reference          Reference                                        Reference

   2005-2009                                                                      1.05 (0.89-1.25)   1.09 (0.92-1.29)                                 1.14 (0.95-1.37)

   2009-2013                                                                      0.88 (0.74-1.04)   0.86 (0.69-1.05)                                 0.98 (0.75-1.29)

  Center^[c](#table-fn10-2054358119875462){ref-type="table-fn"}^                                                                                      

   1                                                                              1.09 (0.97-1.24)   1.10 (0.97-1.25)                                 1.22 (1.01-1.47)

   2                                                                              0.76 (0.64-0.92)   0.78 (0.65-0.93)                                 0.72 (0.58-0.89)

   3                                                                              1.24 (1.08-1.43)   1.18 (1.01-1.37)                                 1.13 (0.96-1.33)

   4                                                                              0.88 (0.76-1.03)   0.89 (0.76-1.04)                                 0.87 (0.74-1.02)

   5                                                                              1.09 (0.96-1.24)   1.11 (0.97-1.28)                                 1.16 (1.00-1.35)

  Center volume: (per 25 patients)                                                                                                                    0.90 (0.78-1.04)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Note.* HR = hazard ratios; CI = confidence interval; ESRD = end-stage renal disease; GN = glomerulonephritis; RVD = renal vascular disease; BMI = body mass index.

Other includes Aboriginal, Indian subcontinent, Pacific Islander, other/Multiracial.

Pretransplant dialysis includes both peritoneal dialysis and hemodialysis.

Center---the reference is the average across all centers.

![Center variation in death-censored graft loss: (A) unadjusted hazard ratios comparing each center versus the average; (B) hazard ratios comparing each center versus the average after adjusting for patient case mix; and (C) hazard ratios comparing each center versus the average after adjusting for patient case mix and center volume.\
*Note.* The reference line at 1 represents average performance across all centers. The outer dots represent 95% confidence intervals. Case mix includes recipient sex, race, age, body mass index, cause of end-stage renal disease, Charlson Index, dialysis required and time on dialysis pretransplant, donor type and donor age, and time period of transplant. Center volume was defined as the total number of transplants performed at a given center in the calendar year before a patient's transplant.](10.1177_2054358119875462-fig3){#fig3-2054358119875462}

Results from the multivariable Cox proportional hazards regression analyses for total mortality are presented in [Table 4](#table4-2054358119875462){ref-type="table"}. Center-specific HRs and 95% CIs obtained from these analyses are displayed graphically in [Figure 4](#fig4-2054358119875462){ref-type="fig"}, showing variation across centers before adjusting for patient case mix, and then after adjusting for patient case mix alone, and then patient case mix plus center volume. The results showed that raw center-specific HRs for total mortality varied significantly across centers (*P* \< .0001) from a minimum of 0.82 to a maximum of 1.16 ([Figure 4A](#fig4-2054358119875462){ref-type="fig"}). Two centers were significantly lesser and the other 2 were significantly more than the average for all centers. From the multivariable models, patient case mix factors found to be significantly associated with total mortality were recipient age and sex, Charlson Index, time on dialysis pretransplant, donor age, and time era of transplant. In univariate (unadjusted models), being Caucasian had worse patient survival HR 1.41 (1.12-1.77) compared to the reference group. The results were similar in multivariable models (with being Caucasian associated with worse survival), although the overall *P* value for race was nonsignificant. After accounting for patient case mix, differences across centers still ranged from 0.85 to 1.11 (*P* = .01). Center volume was not statistically significantly associated with total mortality (HR = 1.04; 95% CI, 0.90-1.20; [Table 4](#table4-2054358119875462){ref-type="table"}). After adjusting for center volume, center-specific HRs ranged from 0.82 to 1.13 and remained statistically significantly different (*P* = .04).

###### 

Center-Specific Hazard Ratios From Multivariable Cox Proportional Hazards Regression Analysis for Total Mortality Over Full Follow-Up (Total Number of Events = 915).

![](10.1177_2054358119875462-table4)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Covariate                                                                        Unadjusted\        Adjusting for patient case mix only (n = 5037)   Adjusting for patient case mix and center volume (n = 5037)
                                                                                   (n = 5037)                                                          
  -------------------------------------------------------------------------------- ------------------ ------------------------------------------------ -------------------------------------------------------------
  Age, (per 5 year increase)                                                       1.35 (1.31-1.39)   1.28 (1.24-1.32)                                 1.28 (1.24-1.32)

  Sex                                                                                                                                                  

   Female                                                                          0.71 (0.62-0.82)   0.85 (0.73-0.98)                                 0.85 (0.73-0.98)

   Male                                                                            Reference          Reference                                        Reference

  Race                                                                                                                                                 

   Caucasian                                                                       1.41 (1.12-1.77)   1.52 (1.19-1.95)                                 1.52 (1.19-1.95)

   African                                                                         0.95 (0.66-1.37)   0.97 (0.66-1.42)                                 0.97 (0.66-1.42)

   Asian                                                                           1.03 (0.73-1.45)   1.34 (0.94-1.92)                                 1.35 (0.94-1.93)

   Other^[a](#table-fn12-2054358119875462){ref-type="table-fn"}^                   Reference          Reference                                        Reference

  Cause of ESRD                                                                                                                                        

   GN                                                                              0.74 (0.60-0.91)   0.72 (0.58-0.89)                                 0.71 (0.58-0.89)

   Diabetes                                                                        2.19 (1.79-2.68)   1.29 (1.02-1.63)                                 1.29 (1.02-1.63)

   Cystic                                                                          0.68 (0.52-0.89)   0.62 (0.47-0.81)                                 0.62 (0.47-0.81)

   RVD                                                                             1.41 (1.11-1.79)   0.95 (0.74-1.22)                                 0.95 (0.74-1.21)

   Other                                                                           Reference          Reference                                        Reference

  BMI                                                                              1.04 (1.03-1.05)   1.01 (0.99-1.03)                                 1.01 (0.99-1.03)

  Charlson Index                                                                   1.46 (1.39-1.53)   1.19 (1.12-1.27)                                 1.19 (1.12-1.27)

  Preemptive transplant                                                            0.35 (0.25-0.47)   0.82 (0.58-1.16)                                 0.82 (0.58-1.16)

  Pretransplant dialysis^[b](#table-fn13-2054358119875462){ref-type="table-fn"}^   Reference          Reference                                        Reference

  Time on dialysis pretransplant (per 1-year increase)                             1.00 (1.00-1.00)   1.07 (1.05-1.10)                                 1.07 (1.05-1.10)

  Donor type                                                                                                                                           

   Living                                                                          0.48 (0.42-0.46)   0.86 (0.72-1.02)                                 0.86 (0.73-1.02)

   Deceased                                                                        Reference          Reference                                        Reference

  Donor age (per 5-year increase)                                                  1.07 (1.04-1.09)   1.04 (1.02-1.07)                                 1.04 (1.02-1.07)

  Time era of transplant                                                                                                                               

   2000-2004                                                                       Reference          Reference                                        Reference

   2005-2009                                                                       1.04 (0.89-1.21)   0.87 (0.74-1.02)                                 0.85 (0.71-1.02)

   2009-2013                                                                       0.98 (0.79-1.22)   0.72 (0.58-0.90)                                 0.69 (0.52-0.92)

  Centre^[c](#table-fn14-2054358119875462){ref-type="table-fn"}^                                                                                       

   1                                                                               0.82 (0.73-0.93)   0.85 (0.75-0.97)                                 0.82 (0.69-0.99)

   2                                                                               1.11 (0.96-1.27)   1.06 (0.92-1.22)                                 1.09 (0.91-1.30)

   3                                                                               1.15 (1.01-1.31)   1.11 (0.97-1.29)                                 1.13 (0.97-1.32)

   4                                                                               1.16 (1.02-1.32)   1.05 (0.92-1.19)                                 1.06 (0.92-1.21)

   5                                                                               0.83 (0.73-0.94)   0.95 (0.83-1.09)                                 0.93 (0.80-1.09)

  Center volume: (per 25 patients)                                                                                                                     1.04 (0.90-1.20)
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Note.* ESRD = end-stage renal disease; GN = glomerulonephritis; RVD = renal vascular disease; BMI = body mass index.

Other includes Aboriginal, Indian subcontinent, Pacific Islander, other/Multiracial.

Pretransplant dialysis includes both peritoneal dialysis and hemodialysis.

Center---the reference is the average across all centers.

![Center variation in total mortality: (A) unadjusted hazard ratios comparing each center versus the average; (B) hazard ratios comparing each center versus the average after adjusting for patient case mix; and (C) hazard ratios comparing each center versus the average after adjusting for patient case mix and center volume.\
*Note.* The reference line at 1 represents average performance across all centers. The outer dots represent 95% confidence intervals. Case mix includes recipient sex, race, age, body mass index, cause of end-stage renal disease, Charlson Index, dialysis required and time on dialysis pretransplant, donor type and donor age, and time period of transplant.](10.1177_2054358119875462-fig4){#fig4-2054358119875462}

Discussion {#section37-2054358119875462}
==========

Our study found statistically significant center variation in the co-primary outcomes death-censored graft loss and total mortality across 5 Ontario kidney transplant centers even after adjusting for patient case mix and center volume. Additionally, there were clinically significant differences in the adjusted HRs across centers. For example, the risk of death-censored graft loss, after adjusting for all covariates, was close to 30% lower than the average at one center (HR = 0.72; 95% CI, 0.58-0.89) compared with 20% higher than the average at another center (HR = 1.22; 95% CI, 1.01-1.47). While CIs were wide, they were indicative of important differences across centers.

These results are similar to what was previously found in a Canadian study by Kim et al,^[@bibr4-2054358119875462]^ which included 5082 participants transplanted across 20 Canadian centers between 1988 and 1997. Their study found significant variation in facility-specific covariate-adjusted HRs for both total graft survival as well as total mortality. Other studies,^[@bibr5-2054358119875462],[@bibr7-2054358119875462],[@bibr17-2054358119875462]^ which have also compared center outcomes, have found conflicting results. Briganti et al^[@bibr17-2054358119875462]^ found significant variation in graft-survival rates across 16 transplant centers in Australia when using a fixed-effects multivariable Cox proportional hazards regression model; however, when hierarchical modeling treating center as random effects was used, there was no longer a significant difference in the outcome. Elinder et al^[@bibr7-2054358119875462]^ describe nonsignificant variation in graft-survival rates across 3 transplant centers in Sweden and a significant difference for mortality. Medcalf et al^[@bibr5-2054358119875462]^ found significant variation for both graft and patient-survival rates across 5 transplant centers when comparing to one reference center. Plausible explanations for the differences in findings include: the time era of transplant, the length of follow-up period, the inclusion and exclusion criteria of the cohort studies, the choice of reference center, and covariates used for adjustment.

Patient and transplant-specific characteristics known to affect graft and patient survival have been well documented.^[@bibr6-2054358119875462],[@bibr7-2054358119875462],[@bibr17-2054358119875462]^ In the study by Gjertson,^[@bibr2-2054358119875462]^ the following patient factors were found to contribute to center variation in outcomes from living donors: recipient race, age, sex, cause of ESRD, obesity status, time on dialysis, donor relationship, donor age, sex, and race. In addition to patient characteristics, the calendar year of transplantation has also been shown to impact variability in graft-survival rates. While our study found some of the same patient case mix factors to be significantly associated with improved graft survival in multivariable models (recipient age, BMI, pretransplant time on dialysis, donor type, and donor age), we were unable to identify which specific patient factors contributed directly to center variation nor were we able to provide a percentage. Patient-survival rates have been found to be influenced by recipient age, comorbidities, and the type of donor (living compared to deceased).^[@bibr33-2054358119875462]^ From the multivariable models, patient case mix factors found to be significantly associated with total mortality were older recipient age and male sex, greater Charlson Index, greater time on dialysis pretransplant, older donor age, and earlier time era of transplant. While the overall *P* value was not significant for race, being Caucasian had worse patient survival compared to the reference group with its CI excluding 1.

Interestingly, we did not detect any independent statistically significant association between a center's transplant volume and either graft survival or patient survival in our adjusted multivariable models. The literature examining whether an association between kidney transplant center volume and posttransplantation outcomes exists was recently summarized in a systematic review.^[@bibr34-2054358119875462]^ While just under half of these prior studies found a positive and significant association between greater volume and graft survival,^[@bibr1-2054358119875462],[@bibr4-2054358119875462],[@bibr18-2054358119875462][@bibr19-2054358119875462][@bibr20-2054358119875462]-[@bibr21-2054358119875462],[@bibr23-2054358119875462]^ the remainder of previous studies included in the review, either found no association between volume and outcome^[@bibr3-2054358119875462],[@bibr6-2054358119875462],[@bibr35-2054358119875462][@bibr36-2054358119875462]-[@bibr37-2054358119875462]^ or were inconclusive.^[@bibr2-2054358119875462],[@bibr17-2054358119875462],[@bibr38-2054358119875462],[@bibr39-2054358119875462]^ We acknowledge that center volume is likely a surrogate marker, as there are many factors that we were unable to measure that may impact quality of care and therefore transplant outcome. Some of these include the infrastructure of the hospital (number of years as a transplant center, number of beds dedicated to transplant patients, and the type of dedicated health care providers for transplant patients), experience of the medical physicians and surgeons caring for the patient in hospital, and the postoperative care in hospital (experience of team caring for the patient), follow-up procedures after discharge (eg, frequency of clinic visits after hospital discharge and the location of transplant follow-up care).

Our study included a cohort of over 5000 patients who underwent primary solitary kidney transplantation in Ontario between 2000 and 2013 and is the first large analysis to examine center variation in kidney transplant outcomes transplanted exclusively beyond the year 2000. This is relevant, given that short-term patient- and graft-survival rates have ameliorated with improvements in the newer immunosuppressive therapies. Furthermore, we included patients who had more than 10 years of follow-up, enabling an assessment of outcomes at 10 years after transplantation. This is important because a previous Canadian study found greater variation in the survival rates across centers with increasing time from transplantation.^[@bibr4-2054358119875462]^

Our study had several limitations. First, there was a high percentage of missing data for certain covariates which precluded the use of a multiple imputation approach and meant that covariates, such as cold ischemia time, panel-reactive antibody, and distance to hospital, which have been found to be associated with graft survival and potentially contribute to a center variation could not be analyzed. Second, the small number of centers included in the analyses meant we could not perform hierarchical modeling. Third, given the nature of our study which used administrative databases, we were unable to take into account some important patient and clinical process variables such as immunosuppressive protocols which may vary at institutions and explain differences in patient outcomes. Fourth, adjustment for all comorbid conditions across centers was challenging, given the nature of the study. and therefore. it is possible that certain factors were not accounted for. Finally, while it was our intention to analyze the association between provider experience and transplant outcome, the estimate used for provider experience was an average of all the different physicians billing for one patient at the time of transplant, as there was not one specific provider who was most responsible for the patient's care. While a shared-care model itself is not a limitation, this type of model hindered our ability to conduct meaningful analyses.

As the number of patients with ESRD continues to increase and the number of available kidneys for transplantation remains steady, optimizing graft-survival rates is essential. While identification of patient factors that affect transplant outcomes is important, such factors are not always modifiable. Examining center factors in association with transplant outcomes is important, as some of these variables may be adjustable. For example, learning that center transplant volume was not associated with graft or patient-survival rates is a key finding and reassuring for patients. While the results from this study are meaningful, they will need to be confirmed using a larger sample of transplant centers. A larger study can be further enriched by including additional data that are not routinely collected and that may explain center variation, for example, by surveying transplant directors about factors such as induction and maintenance immunosuppression protocols and clinic follow-up intervals.

In conclusion, we found significant variation in graft- and patient-survival rates across kidney transplant centers in Ontario. While the association with center volume and graft survival did not reach statistical significance, there was a tendency toward reduced risk of graft loss in centers with higher volumes; however, center volume was not associated with total mortality. We did not find strong support for our hypotheses that neither case mix nor center volume explained some of the variations across the centers. There are other factors, such as provider characteristics, which were not examined in this study that may account for differences in patient and graft survival. Future studies with more granular capture of provider details will be needed to improve our understanding of between-center differences in kidney transplantation.
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